Ascendis Pharma is building a fully integrated, rare disease focused biopharmaceutical company by leveraging our unique technology platform to benefit patients. We are highly focused on meeting unmet needs in diseases where our TransCon technology can make a significant difference in patients’ lives.
We believe our long-acting prodrug versions of current therapies can enable more convenient dosing and improved efficacy through better patient compliance. Our technology may also help to improve safety and tolerability by reducing the potential for injection-site reactions and enabling less frequent dosing.
TransCon Growth Hormone
Our late-stage TransCon Growth Hormone product candidate is a more convenient once-weekly dose of hGH that has demonstrated comparable safety and efficacy to daily hGH. Learn more